Clinical assessment in ischaemic cardiomyopathy

Area of Science:

• Cardiology
• Cardiovascular Disease Research

Background:

• Heart failure and associated mortality have significantly increased in the US, primarily driven by coronary artery disease.
• While medical therapies like ACE inhibitors and beta-blockers improve outcomes for left ventricular (LV) dysfunction, they offer modest benefits for severe ischaemic cardiomyopathy.
• Impaired LV function in these patients may not be irreversible, as suggested by improvements post-coronary revascularization.

Purpose of the Study:

• To highlight the importance of diagnostic testing for myocardial viability.
• To emphasize the role of assessing viable myocardium in chronic coronary artery disease patients with LV dysfunction.

Main Methods:

• Review of existing medical literature and clinical observations.
• Analysis of treatment outcomes following coronary revascularization procedures.

Main Results:

• Coronary artery disease is the leading cause of heart failure, accounting for up to 60% of cases.
• Medical therapies provide only modest improvements for severe ischaemic cardiomyopathy.
• Improvements in systolic function after revascularization suggest that LV dysfunction can be reversible.

Conclusions:

• Diagnostic testing for myocardial viability is essential for managing patients with chronic coronary artery disease and LV dysfunction.
• Identifying viable myocardium aids in clinical decision-making for patients with severe ischaemic cardiomyopathy.